AstraZeneca Selects Cambridge, UK for New Global R&D Center and Corporate HQ
The multimillion investment in a facility in Cambridge is part of the company’s move to create strategic global R&D centers in the UK, US and Sweden.
AstraZeneca has announced that Cambridge, United Kingdom will be the location for the company's new UK-based global R&D center and corporate headquarters. The new £330 million ($516 million) facility in Cambridge will bring together AstraZeneca’s small-molecule and biologics R&D activity.
The purpose-built facility, which will be located in the Cambridge Biomedical Campus, is part of the company’s previously announced plan to create strategic global R&D centers in the UK, US, and Sweden. By 2016, the new site will house a workforce of approximately 2000. The site will be the new UK home for biologics research and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm. MedImmune already employs approximately 500 people at Granta Park, to the southeast of Cambridge.
The new facility will also become the company’s largest center for oncology research and will also focus on cardiovascular and metabolic diseases, respiratory, inflammation, and autoimmune diseases as well as conditions of the central nervous system. Work carried out in Cambridge will include medicinal chemistry and high-throughput screening, and the facility will accommodate a number of AstraZeneca’s preclinical research capabilities. Other global functions will join the research and development teams at the new facility, and Cambridge will become AstraZeneca’s corporate headquarters.
The Cambridge Biomedical Campus site is home to research, academic, and healthcare organizations, including the University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, the Medical Research Council (MRC) Laboratory of Molecular Biology, the Wellcome Trust–MRC Institute of Metabolic Science, and the Cancer Research UK Cambridge Institute. The AstraZeneca facility will occupy approximately 11 acres of the 70-acre campus.
“Cambridge competes on the global stage as a respected innovation hub for life sciences, and our choice of site puts us at the heart of this important ecosystem, providing valuable collaboration opportunities,” said AstraZeneca CEO Pascal Soriot, in a press statement.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
